Immunogenicity of rat-neu(+) mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment

The use of Trastuzumab (Herceptin), a monoclonal antibody (mAb) targeting HER2/neu, results in an increased median survival in Her2(+) breast cancer patients. The tumour mutational burden and the presence of tumour infiltrating lymphocytes (TILs) clearly correlate with response to trastuzumab. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sow, Heng Sheng, Benonisson, Hreinn, Brouwers, Conny, Linssen, Margot M., Camps, Marcel, Breukel, Cor, Claassens, Jill, van Hall, Thorbald, Ossendorp, Ferry, Fransen, Marieke F., Verbeek, J. Sjef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054273/
https://www.ncbi.nlm.nih.gov/pubmed/32127568
http://dx.doi.org/10.1038/s41598-020-60893-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054273/
https://www.ncbi.nlm.nih.gov/pubmed/32127568
http://dx.doi.org/10.1038/s41598-020-60893-8

Ejemplares similares